These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30118545)

  • 21. Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.
    Megiorni F; McDowell HP; Camero S; Mannarino O; Ceccarelli S; Paiano M; Losty PD; Pizer B; Shukla R; Pizzuti A; Clerico A; Dominici C
    J Exp Clin Cancer Res; 2015 Oct; 34():112. PubMed ID: 26445453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A potent IκB kinase-β inhibitor labeled with carbon-14 and deuterium.
    Latli B; Eriksson M; Hrapchak M; Busacca CA; Senanayake CH
    J Labelled Comp Radiopharm; 2016 Jun; 59(8):300-4. PubMed ID: 27073120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis of stable isotope labeled D
    Tu Y; Zhong J; Wang H; Pan J; Xu Z; Yang W; Luo Y
    J Labelled Comp Radiopharm; 2016 Nov; 59(13):546-551. PubMed ID: 27739098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual potent c-Met and ALK inhibitors: from common feature pharmacophore modeling to structure based virtual screening.
    Pirhadi S; Damghani T; Avestan MS; Sharifi S
    J Recept Signal Transduct Res; 2020 Aug; 40(4):357-364. PubMed ID: 32126881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crizotinib-induced erosive esophagitis in a pediatric patient with neuroblastoma.
    Lubcke N; Van Camp K
    J Oncol Pharm Pract; 2019 Apr; 25(3):724-726. PubMed ID: 29357780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.
    Jänne PA; Shaw AT; Camidge DR; Giaccone G; Shreeve SM; Tang Y; Goldberg Z; Martini JF; Xu H; James LP; Solomon BJ
    J Thorac Oncol; 2016 May; 11(5):737-747. PubMed ID: 26899759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase I/II Study of Crizotinib for Recurrent or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma and a Phase I Study of Crizotinib for Recurrent or Refractory Neuroblastoma : Study Protocol for a Multicenter Single-arm Open-label Trial.
    Sekimizu M; Osumi T; Fukano R; Koga Y; Kada A; Saito AM; Mori T
    Acta Med Okayama; 2018 Aug; 72(4):431-436. PubMed ID: 30140094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of Potent, Selective, and Brain-Penetrant 1 H-Pyrazol-5-yl-1 H-pyrrolo[2,3- b]pyridines as Anaplastic Lymphoma Kinase (ALK) Inhibitors.
    Fushimi M; Fujimori I; Wakabayashi T; Hasui T; Kawakita Y; Imamura K; Kato T; Murakami M; Ishii T; Kikko Y; Kasahara M; Nakatani A; Hiura Y; Miyamoto M; Saikatendu K; Zou H; Lane SW; Lawson JD; Imoto H
    J Med Chem; 2019 May; 62(10):4915-4935. PubMed ID: 31009559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370).
    Spigel DR; Reynolds C; Waterhouse D; Garon EB; Chandler J; Babu S; Thurmes P; Spira A; Jotte R; Zhu J; Lin WH; Blumenschein G
    J Thorac Oncol; 2018 May; 13(5):682-688. PubMed ID: 29518553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
    Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
    J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.
    Le X; Freed JA; VanderLaan PA; Huberman MS; Rangachari D; Jorge SE; Lucena-Araujo AR; Kobayashi SS; Balasubramanian S; He J; Chudnovsky Y; Miller VA; Ali SM; Costa DB
    Clin Lung Cancer; 2015 Sep; 16(5):e105-9. PubMed ID: 25922291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Crizotinib in ALK
    Theilen TM; Soerensen J; Bochennek K; Becker M; Schwabe D; Rolle U; Klingebiel T; Lehrnbecher T
    Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.
    Kang J; Chen HJ; Zhang XC; Su J; Zhou Q; Tu HY; Wang Z; Wang BC; Zhong WZ; Yang XN; Chen ZH; Ding Y; Wu X; Wang M; Fu JG; Yang Z; Zhang X; Shao YW; Wu YL; Yang JJ
    Thorac Cancer; 2018 Sep; 9(9):1093-1103. PubMed ID: 29978950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
    Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
    PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and biological evaluation of glycol diaryl ethers as novel anti-cancer agents through structure-based optimization of crizotinib.
    Liu S; Liu X; Zhang X; Shi M; Wang H; Liu Y
    Chem Biol Drug Des; 2018 Dec; 92(6):1972-1980. PubMed ID: 30025202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
    Peters S; Zimmermann S
    Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
    Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
    Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.
    Kogita A; Togashi Y; Hayashi H; Banno E; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
    Int J Oncol; 2015 Mar; 46(3):1025-30. PubMed ID: 25502629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of anaplastic lymphoma kinase promotes apoptosis and suppresses proliferation in human hepatocellular carcinoma.
    Yu Z; Zhao R
    Anticancer Drugs; 2018 Jul; 29(6):513-519. PubMed ID: 29570100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K; Kolesar JM
    Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.